Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: Impact of biological parameters on clinical outcome

摘要

Recent advances in the biology of chronic lymphocyte leukemia (CLL) revolutionized our understanding of the disease and opened place to risk-adapted treatment. While the gold standard therapy in fit patients is still fludarabine, cyclophos-phamide, and rituximab (FCR), large subset of CLL patients is unable to complete the planned treatment because of excessive toxicity associated with elderly age and comorbidity [1-3]. Moreover, FCR regimen did not offer an improvement in terms of OR rate respect to fludarabine and cyclophosphamide (FC) in patients with mutated IGHV and standard risk FISH [4].